Y-mAbs Therapeutics, Inc.

The future of radiopharmaceuticals is bright. Let’s talk about it at SXSW?2025! Join Y-mAbs Therapeutics, Inc.?for an exclusive fireside chat, "Turning up the Volume on Radiopharmaceuticals," featuring Michael Rossi, President and CEO of Y-mAbs Therapeutics, Inc.,?and moderated by Alice Park, Senior Health Correspondent?of Time Inc. The conversation will explore the latest innovations, potential advantages over traditional cancer treatments, and what’s next for this game-changing field. The fireside chat will take place on Tuesday, March 11th, 2025, from 11:30 AM – 12:30 PM CT in the JW Marriott, Salon D. To learn more, visit: https://lnkd.in/eRuZ9NE9? #YmAbs #SXSW #SXSW2025 #Radiopharmaceuticals #CancerInnovation #Radiopharma

Today, we reported financial results and recent corporate developments for the fourth quarter and full year 2024. Driven by our commitment to delivering innovative cancer therapies, we continue to work towards improving patient outcomes and expanding treatment options. With the recent establishment of two dedicated business units, we are well positioned to drive commercial success and accelerate innovation in radiopharmaceuticals. We remain focused on expanding global access of DANYELZA and advancing our SADA PRIT platform through clinical development. View our full press release here: https://bit.ly/4h9rpdi To listen to the replay of our webcast, visit: https://bit.ly/4bq1vAS

Y-mAbs Therapeutics, Inc. strongly supports the Give Kids a Chance Act?of 2025, a landmark bill to accelerate pediatric cancer treatments and expand access to life-saving therapies for children battling rare diseases. The bill combines two critical initiatives — the original Give Kids a Chance Act and the Creating Hope Reauthorization Act — to accelerate therapy development for pediatric rare diseases, improve outcomes for patients, and close gaps in pediatric drug research. Read more about the bill here: https://bit.ly/41jOuFB Show your support for children battling cancer and other rare diseases by filling out this quick survey asking Congress to pass the Give Kids a Chance Act in the March 2025 funding bill: https://lnkd.in/dus8Ea_k

At Y-mAbs Therapeutics, Inc., people come first – the people who make up our company and the patients and customers we serve. The destruction from the recent wildfires in Los Angeles, CA is unimaginable for everyone, and even worse for those families caring for a child who has cancer.?As part of our longstanding commitment to supporting patients facing the challenges of childhood cancer and their families, we are very proud to support Pinky Swear Foundation to help families in Los Angeles navigate both the emotional and financial burdens of cancer treatment, especially during these difficult times. This donation is not simply from Y-mAbs. This donation has been made on behalf of each and every one of our incredible 110 team members. Their dedication to improving the lives of children with cancer extends beyond our work in the lab. We truly appreciate the mission of Pinky Swear Foundation and the meaningful support they provide to families during challenging times. To learn more about the encouragement and support Pinky Swear Foundation provides to children and families facing cancer, visit: https://pinkyswear.org/ #PinkySwearFoundation #ChildhoodCancerAwareness

Today, as we recognize Neuroblastoma Awareness Day and kick-off Neuroblastoma Awareness Week, we honor the children who are currently battling or have battled this terrible disease along with their families and communities. We also honor the resilience of those lost to neuroblastoma and their impactful legacy. Hundreds of children are diagnosed with neuroblastoma every year. While considered a rare disease, neuroblastoma is one of the leading causes of death in children with cancer. ? Today and every day, Y-mAbs Therapeutics, Inc. stands with the patients, families, and advocates in this childhood cancer community in support of their dedicated efforts to continue raising awareness of neuroblastoma. Every breakthrough in neuroblastoma research brings us closer to new possibilities for treatment and new hope for families. We remain committed to pushing the boundaries of science to make a meaningful difference. ? Join us in spreading awareness and supporting the neuroblastoma community. Together, we can shine a light on this rare disease and the urgent need for continued innovation. ? Learn more about Neuroblastoma Awareness Day and Week from Neuroblastoma Australia?here: https://bit.ly/42DNNbd ? #NeuroblastomaAwareness #PediatricCancer #InnovationInOncology #HopeForKi

Y-mAbs Therapeutics, Inc.?announced the presentation of?preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster today at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and American College of Nuclear Medicine (ACNM) Annual Meeting?in Anaheim, CA. This research is an important step forward in our commitment to advancing next-generation pretargeted radiopharmaceuticals with the potential to benefit both pediatric and adult cancer patients. To learn more, see our press release here: https://bit.ly/4glB3cr #SNMMI2025 #radiopharmaceuticals #radioimmunotherapy

Our President and CEO?Michael Rossi?will present at the 43rd Annual?J.P. Morgan Healthcare Conference?on Wednesday, January 15th at 5:15 p.m. PT.?Y-mAbs Therapeutics, Inc.?management will also participate in one-on-one investor meetings throughout the conference. Join the conversation as we share the latest innovations driving our mission to transform cancer care and improve outcomes for patients. #radiopharmaceuticals #radioimmunotherapy #pediatriconcology Read our press release for more information: https://bit.ly/49Nc5Bj #JPM2025

Y-mAbs Therapeutics, Inc. today announced two posters to be highlighted at the 66th American Society of Hematology Annual Meeting and Exposition being held on December 7–10, 2024 in San Diego, California. These posters presenting CD38-SADA in Non-Hodgkin Lymphoma preclinical data and our CD38-SADA Phase 1 trial-in-progress represent an important step as we advance this second program from our novel SADA PRIT technology platform through clinical development. To learn more, see our press release here: https://bit.ly/3Vud834 #ASH24 #radiopharmaceuticals #radioimmunotherapy

Today, we reported financial results and recent corporate developments for the third quarter of 2024. Guided by our mission of improving the lives of patients and their families, we remain committed to advancing our novel SADA PRIT programs through clinical development and expanding global access of DANYELZA for children with relapsed/refractory high-risk neuroblastoma. ? View our full press release here: https://lnkd.in/g5jCHfbv ? To listen to the replay of our webcast, visit: https://bit.ly/40BKSyU

Ready to connect at The International Society of Paediatric Oncology (SIOP) Congress happening in Honolulu, HI, now through October 20, 2024? Stop by the Y-mAbs’ exhibit and say hi! https://siop-congress.org/ #SIOP2024 #Ymabs #PediatricCancer #RareDiseaseAwareness #childhoodcancer #cancerawareness #pediatriconcology